These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23183428)

  • 1. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
    Larsen JT; Kumar SK; Dispenzieri A; Kyle RA; Katzmann JA; Rajkumar SV
    Leukemia; 2013 Apr; 27(4):941-6. PubMed ID: 23183428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.
    Henriot B; Rouger E; Rousseau C; Escoffre M; Sébillot M; Bendavid C; Minvielle S; Avet-Loiseau H; Decaux O; Moreau C
    Clin Chem Lab Med; 2019 Aug; 57(9):1397-1405. PubMed ID: 30973821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.
    Dispenzieri A; Kyle RA; Katzmann JA; Therneau TM; Larson D; Benson J; Clark RJ; Melton LJ; Gertz MA; Kumar SK; Fonseca R; Jelinek DF; Rajkumar SV
    Blood; 2008 Jan; 111(2):785-9. PubMed ID: 17942755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma.
    Yadav P; Cockwell P; Cook M; Pinney J; Giles H; Aung YS; Cairns D; Owen RG; Davies FE; Jackson GH; Child JA; Morgan GJ; Drayson MT
    BMC Nephrol; 2018 Jul; 19(1):178. PubMed ID: 30012107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
    Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
    BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study.
    Kaplan B; Golderman S; Aizenbud B; Esev K; Kukuy O; Leiba M; Livneh A; Ben-Zvi I
    Am J Hematol; 2014 Sep; 89(9):882-8. PubMed ID: 24866208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
    Mateos MV; Kumar S; Dimopoulos MA; González-Calle V; Kastritis E; Hajek R; De Larrea CF; Morgan GJ; Merlini G; Goldschmidt H; Geraldes C; Gozzetti A; Kyriakou C; Garderet L; Hansson M; Zamagni E; Fantl D; Leleu X; Kim BS; Esteves G; Ludwig H; Usmani S; Min CK; Qi M; Ukropec J; Weiss BM; Rajkumar SV; Durie BGM; San-Miguel J
    Blood Cancer J; 2020 Oct; 10(10):102. PubMed ID: 33067414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains.
    Pratt G; Mead GP; Godfrey KR; Hu Y; Evans ND; Chappell MJ; Lovell R; Bradwell AR
    Leuk Lymphoma; 2006 Jan; 47(1):21-8. PubMed ID: 16321823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Free light chains ratio as a marker to estimate prognosis and survival in patients with multiple myeloma and primary amyloidosis.
    Radovic V; Mijuskovic Z; Tukic Lj; Djurdjevic P; Stojanovic J; Zlatkovic M
    J BUON; 2012; 17(1):110-5. PubMed ID: 22517703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.
    Kastritis E; Terpos E; Moulopoulos L; Spyropoulou-Vlachou M; Kanellias N; Eleftherakis-Papaiakovou E; Gkotzamanidou M; Migkou M; Gavriatopoulou M; Roussou M; Tasidou A; Dimopoulos MA
    Leukemia; 2013 Apr; 27(4):947-53. PubMed ID: 23183429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
    Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
    Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appraisal of immunoglobulin free light chain as a marker of response.
    Dispenzieri A; Zhang L; Katzmann JA; Snyder M; Blood E; Degoey R; Henderson K; Kyle RA; Oken MM; Bradwell AR; Greipp PR
    Blood; 2008 May; 111(10):4908-15. PubMed ID: 18364469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
    Miyazaki K; Suzuki K
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):293-296. PubMed ID: 29472112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma.
    Schieferdecker A; Hörber S; Ums M; Besemer B; Bokemeyer C; Peter A; Weisel K
    Blood Cancer J; 2020 Jan; 10(1):2. PubMed ID: 31915365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
    Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
    Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma.
    Caillon H; Avet-Loiseau H; Attal M; Moreau P; Decaux O; Dejoie T
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e228-e237. PubMed ID: 30799237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.
    Sørrig R; Klausen TW; Salomo M; Vangsted AJ; Østergaard B; Gregersen H; Frølund UC; Andersen NF; Helleberg C; Andersen KT; Pedersen RS; Pedersen P; Abildgaard N; Gimsing P;
    Eur J Haematol; 2016 Sep; 97(3):303-9. PubMed ID: 26710662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma.
    Kumar S; Zhang L; Dispenzieri A; Van Wier S; Katzmann JA; Snyder M; Blood E; DeGoey R; Henderson K; Kyle RA; Bradwell AR; Greipp PR; Rajkumar SV; Fonseca R
    Leukemia; 2010 Aug; 24(8):1498-505. PubMed ID: 20520636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serum free light chains for diagnosis and follow-up of multiple myeloma].
    Jung S; Kim M; Lim J; Kim Y; Han K; Min CK; Min WS
    Korean J Lab Med; 2008 Jun; 28(3):169-73. PubMed ID: 18594166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.